Shaare Zedek Medical Center in Jerusalem has announced a strategic partnership with Imagene AI to strengthen cancer research and patient care through multimodal artificial intelligence and real-world clinical data. The collaboration aims to improve early detection of complex cancer mutations and expand the use of personalized medicine.
AI-powered cancer research in Jerusalem
The new initiative combines Shaare Zedek’s clinical data and digital infrastructure with the Oncology Intelligence Suite developed by Imagene AI. The platform enables rapid data analysis, discovery of biological markers and improved matching of therapies for oncology patients.
Dr. Renana Ofen, CEO of Madait – Shaare Zedek’s innovation arm – said, “Our vision is to improve patient care through innovation. The partnership with Imagene AI allows us to integrate advanced AI tools into clinical workflows, empower our doctors and researchers and accelerate data-driven discoveries for the benefit of patients.”
Personalized treatment for cancer patients
Under the agreement, Madait will provide Imagene AI access to curated clinical data with full privacy and regulatory compliance. In return, Shaare Zedek’s researchers will use the OI Suite to test hypotheses, analyze datasets and build predictive models for various cancer types.
Dean Biton, co-founder and CEO of Imagene AI, explained, “This collaboration strengthens our mission to transform oncology research using real-world data and multimodal AI. Together with Shaare Zedek, we are bringing personalized medicine closer to the patient’s bedside.”
Imagene AI continues to expand its multimodal medical data repository, which includes pathology images, genetic information and clinical records. The growing dataset supports AI-driven cancer discovery and helps develop advanced treatment insights.
